Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Callitas Health Inc MPHMF

Energy Healthcare Biotechnology
Callitas Health Inc is a Canada-based company that is primarily engaged in integrated clinical-stage pharmaceutical development and over-the-counter (OTC) consumer goods marketing. The Company provides biomedical technologies and products. The Company offers drug treatments for obesity, infertility, intimacy issues, weight management, female sexual dysfunction solutions and women wellness.


GREY:MPHMF - Post by User

Callitas Health Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by YoloRoloon Mar 06, 2017 10:13am
115 Views
Post# 25936535

RE:News

RE:News
Jimmysgirl wrote: M Pharmaceutical Inc. Appoints Kim Whittemore of San Diego, California to Its Board of Directors Fertility and weight management...2 big issues in healthcare..no pun intended. Might be slow movement, but I'm going to hang on to this one.

 
Was hoping it be news about this
'
  • With significant assistance from Camargo Pharmaceutical Services the PIND meeting package for our reformulated Orlistat (C-103) has been completed and delivered to the FDA investigator.
  • The FDA is scheduled to respond to our PIND package by March 6, 2017.

Read more at https://www.stockhouse.com/news/press-releases/2017/02/10/m-pharmaceutical-inc-provides-strategic-report-to-shareholders-highlighting#1pMwFXXFdAzi1WXh.99'

maybe within this week hopefully we hear good news

YRolo
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities